Skip to content

Clinical study on treating novel coronavirus pneumonia with pulmonary fibrosis with the help of Zhuyang Bufei Chubi granule

Clinical study on treating novel coronavirus pneumonia with pulmonary fibrosis with the help of Zhuyang Bufei Chubi granule

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043241
Enrollment
Unknown
Registered
2021-02-09
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel coronavirus pneumonia in convalescence stage of pulmonary fibrosis

Interventions

case series:Nil

Sponsors

Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. It was in accordance with the diagnostic criteria of Western medicine; 2. According to the diagnostic criteria of traditional Chinese medicine; 3. In the past one week, CT showed that there was still inflammation / pulmonary fibrosis in the lung; 4. The age ranged from 18 to 80 years (including boundary value); 5. Informed and voluntary consent to participate in the implementation of the program, signed informed consent. Only those who meet the above four requirements can be included.

Exclusion criteria

Exclusion criteria: 1. Patients with allergy to Chinese Herbal Pieces in the prescription; 2. Pregnant women; 3. Dependent on mechanical ventilation to maintain lung function, such as ventilator; 4. Disabled people who can't complete the collection of efficacy evaluation indicators; 5. Mental state can not cooperate, suffering from mental illness, no self-control, can not express clearly; 6. Participating in other clinical drug trials; 7. According to the judgment of the researchers, there will be patients with complications or poor compliance that affect the efficacy and safety evaluation. 8. Patients who could not cooperate with the researchers to complete the follow-up. Any one of the above should be excluded.

Design outcomes

Primary

MeasureTime frame
Lung CT Score;

Secondary

MeasureTime frame
Evaluation criteria of disease efficacy;Evaluation standard of TCM syndrome curative effect;Six minute walking distance change;Blood oxygen saturation monitoring;The change of nucleic acid and antibody.;Changes of serum related indexes;mMRC, anxiety, depression, sleep, fatigue evaluation;

Countries

China

Contacts

Public ContactWang Tan

Affiliated Hospital of Changchun University of Traditional Chinese Medicine

1357979767@qq.com+86 15904312786

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026